Syros Pharmaceuticals Inc. [NASDAQ: SYRS] gained 7.94% or 1.02 points to close at $13.80 with a heavy trading volume of 2534496 shares. The company report on August 6, 2020 that Syros Reports Second Quarter 2020 Financial Results and Highlights Key Accomplishments and Upcoming Milestones.
Initiated Enrollment in Phase 1 Dose-Escalation Cohort Evaluating SY-5609 and Fulvestrant in Treatment-Resistant HR-Positive Breast Cancer Patients .
On Track to Report Clinical Data for SY-1425 and SY-5609 in Fourth Quarter of 2020.
It opened the trading session at $12.98, the shares rose to $14.5494 and dropped to $12.73, the range by which the price of stock traded the whole day. The daily chart for SYRS points out that the company has recorded 92.47% gains over the past six months. However, it is still -223.94% lower than its most recent low trading price.
If we look at the average trading volume of 317.51K shares, SYRS reached to a volume of 2534496 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Syros Pharmaceuticals Inc. [SYRS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SYRS shares is $12.86 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SYRS stock is a recommendation set at 2.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Wedbush have made an estimate for Syros Pharmaceuticals Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on January 17, 2020. While these analysts kept the previous recommendation, JMP Securities raised their target price to Mkt Outperform. The new note on the price target was released on March 08, 2019, representing the official price target for Syros Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $13, while Oppenheimer analysts kept a Outperform rating on SYRS stock.
The Average True Range (ATR) for Syros Pharmaceuticals Inc. is set at 0.82, with the Price to Sales ratio for SYRS stock in the period of the last 12 months amounting to 96.96. The Price to Book ratio for the last quarter was 10.07.
Trading performance analysis for SYRS stock
Syros Pharmaceuticals Inc. [SYRS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 14.90. With this latest performance, SYRS shares gained by 11.02% in over the last four-week period, additionally plugging by 92.47% over the last 6 months – not to mention a rise of 23.55% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SYRS stock in for the last two-week period is set at 68.77, with the RSI for the last a single of trading hit 74.46, and the three-weeks RSI is set at 64.89 for Syros Pharmaceuticals Inc. [SYRS]. The present Moving Average for the last 50 days of trading for this stock 11.06, while it was recorded at 12.53 for the last single week of trading, and 7.99 for the last 200 days.
Syros Pharmaceuticals Inc. [SYRS]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Syros Pharmaceuticals Inc. [SYRS] shares currently have an operating margin of -3922.35. Syros Pharmaceuticals Inc.’s Net Margin is presently recorded at -3806.16.
Return on Total Capital for SYRS is now -84.63, given the latest momentum, and Return on Invested Capital for the company is -82.70. Return on Equity for this stock declined to -95.63, with Return on Assets sitting at -58.77. When it comes to the capital structure of this company, Syros Pharmaceuticals Inc. [SYRS] has a Total Debt to Total Equity ratio set at 32.73. Additionally, SYRS Total Debt to Total Capital is recorded at 24.66, with Total Debt to Total Assets ending up at 17.28. Long-Term Debt to Equity for the company is recorded at 31.12, with the Long-Term Debt to Total Capital now at 23.44.
Reflecting on the efficiency of the workforce at the company, Syros Pharmaceuticals Inc. [SYRS] managed to generate an average of -$908,892 per employee. Receivables Turnover for the company is 0.20 with a Total Asset Turnover recorded at a value of 0.02.Syros Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.80 and a Current Ratio set at 4.80.
Syros Pharmaceuticals Inc. [SYRS]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Syros Pharmaceuticals Inc. posted -0.47/share EPS, while the average EPS was predicted by analysts to be reported at -0.48/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 2.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SYRS.
An analysis of insider ownership at Syros Pharmaceuticals Inc. [SYRS]
There are presently around $617 million, or 89.50% of SYRS stock, in the hands of institutional investors. The top three institutional holders of SYRS stocks are: ARK INVESTMENT MANAGEMENT LLC with ownership of 8,513,133, which is approximately 44.305% of the company’s market cap and around 0.80% of the total institutional ownership; FMR LLC, holding 6,623,200 shares of the stock with an approximate value of $91.4 million in SYRS stocks shares; and SUMITOMO MITSUI TRUST HOLDINGS, INC., currently with $65.2 million in SYRS stock with ownership of nearly -4.07% of the company’s market capitalization.
Positions in Syros Pharmaceuticals Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 57 institutional holders increased their position in Syros Pharmaceuticals Inc. [NASDAQ:SYRS] by around 5,592,464 shares. Additionally, 21 investors decreased positions by around 5,781,426 shares, while 7 investors held positions by with 33,316,444 shares. The mentioned changes placed institutional holdings at 44,690,334 shares, according to the latest SEC report filing. SYRS stock had 20 new institutional investments in for a total of 904,155 shares, while 5 institutional investors sold positions of 1,389,367 shares during the same period.